RheumNow’s expanded coverage of the annual #ACR2020 meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA 1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks 2⃣Similar improvement in UPA 15mg vs. 30mg 3⃣Both doses similar or > Adalimumab @RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0

The lung-joint axis in RA just keeps on getting stronger Lung ACPA present in early untreated RA/CSA: crossreact acetylated/carbamylated antigens differ in effects on cell types (neut activation, fibroblasts, osteoclasts) Isn't lung ACPA fascinating? #ACR20 ABST1445 @RheumNow https://t.co/9VKSRYlndT

Dr. Jas Singh has shown theres been a decline In-Hospital Mortality in Vasculitis patients over 17 yrs (1998-2014) (using NIS data) #ACR20 Abst#1423 @jasvindermd https://t.co/rMJX5lRrLY https://t.co/aE2rJrMdDh

• https://meet.acrconvergence.org/meetings/virtual/f4THnkckQDBmX5bEK

National Inpatient Sample claims: ANCA Assoc vasculitis pts hospitalized with acute MI (AMI) had a no increase in mortality rate (5.3% vs. 4.7%) during 2016-2017, suggesting potentially better control w/ new meds (RTX), less steroids #ACR20 Abstr#1424 https://t.co/TYELUAjm9d

• https://meet.acrconvergence.org/meetings/virtual/wPtHfjt3Hp4fXBvcn

Using National Inpatient Sample (NIS) claims, SSc pts hospitalized with acute MI (AMI) had a higher unadjusted inpatient mortality rate (9.17% vs. 4.68%; p=0.001)( (aOR=2.02) #ACR20 Abstr#1390 https://t.co/qWUMkJR40d

• https://meet.acrconvergence.org/meetings/virtual/SgtHW8Sz524uXMjWu

Treat-to-target trials keep getting harder: - rheum attitudes changed by prev trials so usual care is already v good - ?less inflamm dx - more ambitious goals ASDAS LDA/40/20 and cost-effective not enough? TICOSPA 'failed' a very high hurdle @annamolto #ACR20 ABST1444 @RheumNow https://t.co/NWSUvAtouR

Hispanic/Latino hospitalization rates are overwhelming but not surprising given the huge health care disparities our community faces. #ACR20 #DrFaucisaidso https://t.co/jEVx7cCh7a

Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1

• https://meet.acrconvergence.org/meetings/virtual/wtv3TtGdj9h5scjeN

1yr results using anti-IL-23 Guselkumab shows the same ACR 20/50/70 responses regardless of prior TNF inhibitor failure. #ACR20 #Abstr#1344 https://t.co/OvgJ53wwmU https://t.co/JdajDONWap

• https://meet.acrconvergence.org/meetings/virtual/EYqpgEqjq5HKr9KnK

Dr. M. “Peggy” Crow’s #StateofArt lecture at #ACR20 reminds us that HCQ is the foundation of tx, to keep prednisone goal < 7.5mg/d, and that BEL works best in early dz (< 2 yrs) Summary slide provided. https://t.co/3LbWqwwOsr

We were always taught that rheumatic disease ILD is v bad in pregnancy. Fetal outcomes are def bad in severe ILD, but no maternal deaths/few Cx. May not need to avoid pregnancy/electively terminate! Largest-to-date cohort @dukemedicine n=94 @drbags71 #ACR20 ABST1446 @RheumNow https://t.co/E7BDHn8KJb

RheumNow’s expanded coverage of the annual #ACR2020 meeting is sponsored in part by @bmsnews, @HorizonNews, @SanofiGenzyme, @Novartis. All content chosen by RheumNow & its Faculty.